Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.

Authors :: Villani S
Zanotta N
Ambrogi F
Comar M
Franciotta D
Dolci M
Cason C
Ticozzi R
Ferrante P
Delbue S
Source :: Journal of neuroimmunology [J Neuroimmunol] 2017 Sep 15; Vol. 310, pp. 91-96. Date of Electronic Publication: 2017 Jul 01.
Publication Year :: 2017
Abstract: Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.<br /> (Copyright © 2017 Elsevier B.V. All rights reserved.)

Subjects :: Adult
Antibodies, Viral blood
Antibodies, Viral urine
Female
Follow-Up Studies
Humans
Intercellular Signaling Peptides and Proteins metabolism
JC Virus genetics
JC Virus immunology
Male
T-Lymphocyte Subsets drug effects
T-Lymphocyte Subsets immunology
Time Factors
Cytokines blood
Immunologic Factors therapeutic use
Multiple Sclerosis blood
Multiple Sclerosis drug therapy
Natalizumab therapeutic use

Full Text Access

Tools